Trial Profile
A Phase I, Blinded Within Dose Groups, Multiple Dose, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Different Titration Schemes of BI 456906 in Patients With Obesity and Overweight
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Mar 2023
Price :
$35
*
At a glance
- Drugs Survodutide (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 05 Nov 2021 Results presented at The Obesity Society: ObesityWeek 2021
- 01 Nov 2021 According to a Zealand Pharma Media Release, the data from this trial will be presented at the Obesity Society Annual Meeting, 2021 as poster by Jorge Arrubla.
- 01 Nov 2021 Results published in the Zealand Pharma Media Release.